At Home Blood Collection Devices Market

At Home Blood Collection Devices Market Outlook: USD 2,767 Million by 2035

The global at home blood collection devices market, valued at USD 857 million in 2025, is projected to reach USD 941 million in 2026 and USD 2,767 million by 2035, with a CAGR of 12.7% during the forecast period 2026 to 2035. Growth is supported by the shift toward decentralized and patient-centric healthcare, rising use of home-based diagnostics and remote patient monitoring, and increasing demand for convenient blood sampling in chronic disease management, preventive healthcare and decentralized clinical research.

Market Report: Key Takeaways

Market Size and Trends

• Liquid blood samples hold the largest share, accounting for nearly 60% of the market by blood sample state.
• The fingerstick method dominates the current market by method of sample collection, reflecting its simplicity, minimally invasive nature and broad compatibility with at home diagnostic and monitoring applications.
• Diagnostic applications currently lead the at home blood collection devices market and are expected to retain the largest share throughout the forecast period, supported by routine testing, chronic-condition monitoring and expanding laboratory validation of self-collected samples.
• North America currently captures more than 65% of the market, while Asia-Pacific is likely to grow at the fastest CAGR during the forecast period.

What are At Home Blood Collection and Devices?

At home blood collection devices are patient-centric medical devices that enable individuals to collect small volumes of blood outside conventional healthcare settings, reducing dependence on clinic-based venipuncture and professional phlebotomy. These devices commonly use fingerstick, push-button and other minimally invasive sampling technologies to collect either liquid capillary blood or dried blood samples. Depending on the collection technology, samples can subsequently be transported to laboratories for diagnostic testing, therapeutic drug monitoring, biomarker analysis, research applications and other laboratory-based assessments. For dried blood spot workflows, specimen collection cards provide a format for collecting and transporting the sample.

The market is gaining momentum as healthcare systems increasingly adopt decentralized diagnostics, home-care and remote patient monitoring. At home collection can improve patient convenience by reducing travel, clinic visits and dependence on trained personnel, making the approach particularly relevant for repeat testing, chronic-condition monitoring, preventive healthcare and decentralized clinical trials. The ability to collect samples remotely can also broaden access for patients who face geographic, mobility or scheduling barriers to conventional blood collection. The current report identifies this shift toward patient-centric and decentralized healthcare as an important contributor to market growth.

Technological innovation is further expanding the capabilities of these devices. Microsampling approaches, including dried blood spot and volumetric microsampling technologies, are reducing the blood volume required for testing, while advances in sample stabilization help preserve specimen integrity during storage and transportation. Depending on the device and analyte, some collection formats can also reduce dependence on refrigerated logistics, simplifying specimen transport from the patient's home to centralized laboratories.

As adoption increases, however, market development will depend on more than patient convenience. Device manufacturers and laboratory partners must ensure consistent sample quality, accurate blood-volume collection, specimen stability, laboratory compatibility, regulatory compliance and reliable logistics. Variability in self-collection can result in rejected samples or repeat testing, while reimbursement and payer coverage remain important considerations for broader adoption. Consequently, companies are increasingly focusing on device usability, sample-quality controls, laboratory integration and scalable distribution models to support wider implementation of at home blood collection across healthcare and research settings.

Market Segmentation

The report segments the at home blood collection devices market into blood sample state, method of sample collection, application area and geographical regions. This structure supports diagnostic companies, device developers, pharmaceutical and biotechnology clinical-development teams, laboratories, healthcare providers, digital-health companies, business-development and procurement teams, and investors evaluating technology adoption and market opportunities.

By Blood Sample State

• Liquid Blood Samples and Dried Blood Samples

By Method of Sample Collection

• Fingerstick Method and Push-button Method

By Application Area

• Diagnostic Applications, Research Applications and Other Applications

By Geographical Regions

• North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America

At Home Blood Collection Devices Market Key Insights

What Factors are Driving Increased Adoption of At Home Blood Collection Devices?

Adoption is driven by advances in microsampling and sample stabilization, rising use of home-based diagnostics and virtual clinical trials, and growing demand for convenient monitoring of chronic conditions. Applications now extend from therapeutic drug monitoring and biomarker testing to preventive-health programs and decentralized research. Improved device design, laboratory compatibility, digital ordering and sample-tracking infrastructure are also reducing workflow friction for patients, healthcare providers and laboratories.

Advancements in Micro sampling and Sample Stabilization

Technologies such as dried blood spot (DBS), volumetric absorptive microsampling (VAMS), capillary collection and plasma-separation formats are expanding the range of tests that can be supported with self-collected samples.

Improvements in sample stabilization, storage and transport are supporting adoption by preserving sample integrity from collection through laboratory analysis. Precise volume control, protective packaging and validated transport conditions can reduce pre-analytical variability and help extend at-home sampling into routine diagnostics, therapeutic drug monitoring, biomarker analysis and decentralized clinical trials.

Regulatory Compliance, Sample Quality and Safety are Critical to Adoption

At home blood collection devices must meet regulatory and quality requirements applicable to their intended use and market. In the US, relevant products are subject to US FDA medical-device requirements; in Europe, manufacturers may need to meet applicable EU device requirements and CE-marking obligations. Quality and risk-management frameworks such as ISO 13485 and ISO 14971 can support device-development controls, while verification and validation should address collection volume, sample integrity, packaging, transport, labeling and usability. Single-use, shielded or enclosed collection mechanisms, clear skin-preparation instructions and appropriate user training can also help reduce contamination and accidental needlestick risk.

Scope, Methodology and Industry Expert Interviews

Roots Analysis defines the at home blood collection devices market as the opportunity across devices and kits that enable blood sample collection and microsampling outside conventional healthcare settings. The market segmentation covers blood sample state, sample collection method, application area and geographic region, as detailed above.

The findings were triangulated across market sizing, device landscape, sample-collection and microsampling methods, laboratory compatibility, patient usability, cost-saving potential, partnerships, funding and regional adoption. Primary and third-party discussions with device developers, laboratory professionals, academics and commercial stakeholders were used to test assumptions and add qualitative context to the market forecast. The key stakeholder perspectives included in the report are listed below:

• Director, Very Small Company, India

In addition, the market report includes transcripts of the following other third-party discussions:

• Chief Executive Officer and Co-Founder, Mid-sized Company, US
• Co-Founder / Chief Technology Officer and Vice President Commercial, Mid-sized Company, US
• Founder, Mid-sized Organization, US
• Chief Executive Officer, Mid-sized Organization, US
• Associate Professor, Very Large Organization, Belgium
• Professor, Large Organization, Rwanda
• Scientific Discipline Director, Very Large Company, US
• Senior Director, Very Large Company, US
• Global Microsampling Specialist, Small Company, US
• Assistant Professor and Outpatient Laboratory Supervisor, Very Large Organization, US

Emphasizing the cost-potential of at home blood collection devices, Virendra Upadhye (Director, Lipomic Healthcare), stated that "According to various research papers, at home blood collection devices are capable of cutting down sample collection expenses to around less than 60% of the original cost. However, I would like to highlight the fact that this cost varies across different geographies. For instance, in India, the cost of home sample collection is very low, as opposed to USA. In addition to the monetary benefits, the convenience of collecting the sample in the comfort of your home at a time of your choice is an important advantage. Often, people are less wary of a finger prick as compared to a venepuncture."

At Home Blood Collection Devices Market Share Insights

Which Blood Sample State Holds the Largest Share of At Home Blood Collection Devices Market?

Liquid blood samples currently account for close to 60% of the market and are expected to remain the leading sample-state segment during the forecast period. Their position reflects broad compatibility with established laboratory workflows and growing availability of devices that enable reliable collection and shipment of liquid capillary blood samples for diagnostics, research and monitoring applications.

Which Application Area Holds the Largest Share of the At Home Blood Collection Devices Market?

Diagnostic applications currently account for the largest share of the market, supported by routine testing, chronic condition monitoring and the growing use of self-collected capillary blood for laboratory analysis. Expansion of digital-health programs, preventive screening and the range of validated analytes that can be measured from small-volume samples is expected to reinforce the segment's position.

Regional Analysis: North America Leads While Asia-Pacific Grows Fastest

North America Leads with More than 65% Market Share

North America currently captures more than 65% of the at home blood collection devices market. The region benefits from advanced diagnostic and laboratory infrastructure, strong adoption of decentralized healthcare and telehealth, established device developers, and high demand for patient-centric testing. Growth in chronic-condition monitoring, preventive healthcare and home-care models is further supporting the use of self-collected samples across clinical and research workflows.

Who are the Key Players in the At Home Blood Collection Devices Market?

Examples of key companies profiled in this market report, arranged in alphabetical order, include EUROIMMUN (a PerkinElmer company), Everlywell, Labcorp, Labonovum, Lameditech, Quest Diagnostics, Spot On Sciences, Tasso, Weavr Health (acquired by Nightingale Health) and YourBio Health (acquired by him & hers). The complete company list is available in the full report together with a searchable Excel database. Other organizations referenced in the underlying analysis may appear in patent, funding, partnership or laboratory-ecosystem discussions and should not be interpreted as endorsements by Roots Analysis.

Report Deliverables and Customization

Alongside the core market report, purchasers receive complimentary Excel data packs covering the at home blood collection device's market landscape, product competitiveness analysis, patent analysis, funding and investments analysis, partnerships and collaborations analysis, and market sizing and opportunity analysis. A complimentary PowerPoint presentation summarizing the key findings is also included, and 15% free customization is available on request. The report is designed to support device manufacturers, diagnostic and laboratory companies, pharmaceutical and biotechnology clinical-development teams, healthcare providers, digital-health companies, business-development and procurement teams, and investors evaluating technology adoption, partnerships and market opportunities.

Report Authorship

This report was authored by Simriti Gupta, part of Roots Analysis's healthcare and pharma research practice. Her work focuses on competitive intelligence, company benchmarking and market forecasting.

Independence and Non-Affiliation

Roots Analysis is an independent market research and consulting firm. This report draws on publicly available information, primary interviews and proprietary analysis. Roots Analysis is not affiliated with, endorsed by or acting on behalf of the US FDA, the European Medicines Agency, or any company, technology or individual named in this report. Company and product names are used for identification and market-analysis purposes only. Nothing in this report should be construed as medical advice.

This report is the second edition covering the at home blood collection devices market and reflects ongoing tracking of technological, regulatory and commercial developments. Roots Analysis maintains its own proprietary primary research process and does not receive compensation from companies profiled in the report in exchange for inclusion or favorable characterization.

Frequently Asked Questions